Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new publication in the Journal of the American Chemical Society (JACS) describing advances in building self-assembling protein cages with atomic precision.
Avimer Bio said the study addresses the challenge of creating predictable protein architectures when building blocks bend during assembly. The team developed algorithms that forecast how alpha-helical protein segments flex, enabling designers to use natural molecular flexibility. This produced cubic protein cages formed from four trimeric protein blocks, twelve subunits in total, with molecular masses above 600 kilodaltons and stability in solution.
High-resolution cryo-electron microscopy at CNIO confirmed that the physical structures matched computational models, with resolutions of 3.0 to 3.9 angstroms and backbone deviations as low as 2 angstroms. The data validated the predicted helix-bending patterns.
The designed cages can present multiple therapeutic proteins in controlled arrangements to cluster cell receptors, supporting applications in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, and in oncology where receptor grouping can stimulate immune responses against tumours.
The platform relies on minimal changes to natural protein sequences and uses a single type of protein subunit per cage, simplifying production and supporting evaluation of immune response.
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
AFYREN ingredient enables global launch of natural propionic acid skincare product
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Teva reports positive Phase 2a data for TEV '408 in celiac disease
AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease